

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of the Company dated 16 December 2025 (the “**Announcement**”) in relation to the sales framework agreement entered into between the Company and China Resources Healthcare Group Limited. Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among others, (i) a letter from the Board setting out the details of the Sales Framework Agreement 2026/2028 and the transactions and the Annual Caps contemplated thereunder, (ii) a letter from the Independent Board Committee to the Independent Shareholders, (iii) a letter from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders, (iv) a notice of the EGM, and (v) other information required under the Listing Rules is expected to be dispatched to the Shareholders within 15 business days after the publication of the Announcement.

However, as additional time is required for the Company to prepare and finalise the information to be included in the Circular, the despatch date of the Circular will be postponed to on or before 15 January 2026.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 9 January 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.